Get the Stockscreener App
44.06
2.44%
1.05
After Hours:
44.06
Mirum Pharmaceuticals Inc stock is traded at $44.06, with a volume of 395.37K.
It is up +2.44% in the last 24 hours and down -12.16% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$43.01
Open:
$42.89
24h Volume:
395.37K
Relative Volume:
0.84
Market Cap:
$2.16B
Revenue:
$307.03M
Net Income/Loss:
$-99.81M
P/E Ratio:
-21.29
EPS:
-2.0695
Net Cash Flow:
$-27.20M
1W Performance:
-2.57%
1M Performance:
-12.16%
6M Performance:
+5.13%
1Y Performance:
+63.55%
1-Day Range:
$42.83
$44.47
1-Week Range:
$42.01
$46.09
52-Week Range:
$23.14
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
44.06 | 2.16B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
(MIRM) Proactive Strategies - Stock Traders Daily
Mirum Pharmaceuticals Strengthens Growth Strategy with Strategic New Hires and Equity Incentives - StockTitan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals director Heron buys $83,661 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $83,661 in stock - Investing.com India
Director’s Bold Move: Major Stock Purchase in Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals’ president sells $676,928 in stock - Investing.com India
Mirum Pharmaceuticals’ president sells $676,928 in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Rhumbline Advisers - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 - Defense World
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report - Yahoo Finance
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - MSN
(MIRM) Technical Data - Stock Traders Daily
Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements - TipRanks
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% After Earnings Miss - MarketBeat
Robert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
H.C. Wainwright lifts Mirum stock target to $72, maintains Buy By Investing.com - Investing.com UK
Mirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects - TipRanks
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results - MarketBeat
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2024 Earnings Call Transcript - Insider Monkey
Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... By GuruFocus - Investing.com Canada
Phocas Financial Corp. Sells 32,190 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals misses Q4 earnings, stock falls - Investing.com India
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Mirum Pharmaceuticals Reports Strong 2024 Growth - TipRanks
Mirum Pharmaceuticals: Strong Financial Performance and Strategic Advancements Drive Buy Rating - TipRanks
Mirum Pharmaceuticals earnings missed by $1.55, revenue topped estimates - Investing.com South Africa
Mirum Pharmaceuticals misses Q4 earnings, stock falls By Investing.com - Investing.com South Africa
Earnings call transcript: Mirum Pharmaceuticals misses Q4 2024 EPS forecast - Investing.com
Mirum Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q4 Revenue $99.4M, vs. FactSet Est of $96.6M - Marketscreener.com
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Yahoo Finance
Mirum Pharmaceuticals' SWOT analysis: FDA approvals boost rare disease stock - Investing.com
Mirum drug for rare genetic disease gains FDA approval - BioPharma Dive
Deal pays off for drugmaker with approval for rare cholesterol-related disease treatment - The Business Journals
Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug - Marketscreener.com
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) - The Bakersfield Californian
Medical Milestone: First Treatment for CTX Patients Shows 20x Better Results Than Placebo - StockTitan
JMP maintains $74 target on Mirum Pharmaceuticals stock By Investing.com - Investing.com South Africa
JMP maintains $74 target on Mirum Pharmaceuticals stock - Investing.com India
FDA approves Mirum’s Ctexli for cerebrotendinous xanthomatosis - Yahoo Finance
US FDA approves Mirum Pharma's genetic disorder drug - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday - MarketBeat
Mirum’s Ctexli wins FDA nod in cerebrotendinous xanthomatosis - BioWorld Online
Mirum Pharmaceuticals' Lipid Storage Disease Treatment Gets FDA Approval -February 21, 2025 at 01:48 pm EST - Marketscreener.com
US FDA approves Mirum Pharma’s genetic disorder drug - KFGO
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):